These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 29678523)
1. Safety and Efficacy of Mesenchymal Stem Cells for Radiation-Induced Xerostomia: A Randomized, Placebo-Controlled Phase 1/2 Trial (MESRIX). Grønhøj C; Jensen DH; Vester-Glowinski P; Jensen SB; Bardow A; Oliveri RS; Fog LM; Specht L; Thomsen C; Darkner S; Jensen M; Müller V; Kiss K; Agander T; Andersen E; Fischer-Nielsen A; von Buchwald C Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):581-592. PubMed ID: 29678523 [TBL] [Abstract][Full Text] [Related]
2. First-in-man mesenchymal stem cells for radiation-induced xerostomia (MESRIX): study protocol for a randomized controlled trial. Grønhøj C; Jensen DH; Glovinski PV; Jensen SB; Bardow A; Oliveri RS; Specht L; Thomsen C; Darkner S; Kiss K; Fischer-Nielsen A; von Buchwald C Trials; 2017 Mar; 18(1):108. PubMed ID: 28270226 [TBL] [Abstract][Full Text] [Related]
3. Mesenchymal Stem/Stromal Cell Therapy for Radiation-Induced Xerostomia in Previous Head and Neck Cancer Patients: A Phase II Randomized, Placebo-Controlled Trial. Jakobsen KK; Carlander AF; Todsen T; Melchiors J; Paaske N; Østergaard Madsen AK; Kloch Bendtsen S; Mordhorst C; Stampe H; Kastrup J; Ekblond A; Haack-Sørensen M; Farhadi M; Maare C; Friborg J; Lynggaard CD; Werner Hauge A; Christensen R; Grønhøj C; von Buchwald C Clin Cancer Res; 2024 May; 30(10):2078-2084. PubMed ID: 38441659 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of mesenchymal stem/stromal cell for radiation-induced hyposalivation and xerostomia in previous head and neck cancer patients (MESRIX-III): a study protocol for a single-centre, double-blinded, randomised, placebo-controlled, phase II study. Jakobsen KK; Carlander AF; Grønhøj C; Todsen T; Melchiors J; Paaske N; Madsen AKØ; Kastrup J; Ekblond A; Haack-Sørensen M; Farhadi M; Maare C; Friborg J; Lynggard CD; von Buchwald C Trials; 2023 Sep; 24(1):567. PubMed ID: 37658468 [TBL] [Abstract][Full Text] [Related]
5. Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial. Lynggaard CD; Grønhøj C; Jensen SB; Christensen R; Specht L; Andersen E; Andersen TT; Ciochon UM; Rathje GS; Hansen AE; Stampe H; Fischer-Nielsen A; von Buchwald C Clin Cancer Res; 2022 Jul; 28(13):2890-2897. PubMed ID: 35486613 [TBL] [Abstract][Full Text] [Related]
6. Phase 1 clinical study of cell therapy with effective-mononuclear cells (E-MNC) for radiogenic xerostomia (first-in-human study) (FIH study on E-MNC therapy for radiogenic xerostomia). Sumita Y; Iwamoto N; Seki M; Yoshida T; Honma R; Iwatake M; Ohba S; Takashi I; Hotokezaka Y; Harada H; Kuroshima S; Nagai K; Asahara T; Atsushi Kawakam I; Asahina I Medicine (Baltimore); 2020 Jun; 99(26):e20788. PubMed ID: 32590759 [TBL] [Abstract][Full Text] [Related]
7. Intraglandular Off-the-Shelf Allogeneic Mesenchymal Stem Cell Treatment in Patients with Radiation-Induced Xerostomia: A Safety Study (MESRIX-II). Lynggaard CD; Grønhøj C; Christensen R; Fischer-Nielsen A; Melchiors J; Specht L; Andersen E; Mortensen J; Oturai P; Barfod GH; Haastrup EK; Møller-Hansen M; Haack-Sørensen M; Ekblond A; Kastrup J; Jensen SB; von Buchwald C Stem Cells Transl Med; 2022 May; 11(5):478-489. PubMed ID: 35435231 [TBL] [Abstract][Full Text] [Related]
8. Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction (MARSH): Study protocol for a phase 1 dose-escalation trial of patients with xerostomia after radiation therapy for head and neck cancer: MARSH: Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction. Blitzer GC; Rogus-Pulia NM; Mattison RJ; Varghese T; Ganz O; Chappell R; Galipeau J; McDowell KA; Meyers RO; Glazer TA; Kimple RJ Cytotherapy; 2022 May; 24(5):534-543. PubMed ID: 35183442 [TBL] [Abstract][Full Text] [Related]
9. Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction (MARSH): A pilot, first-in-human study of interferon gamma-stimulated marrow mesenchymal stromal cells for treatment of radiation-induced xerostomia. Blitzer GC; Glazer T; Burr A; Gustafson S; Ganz O; Meyers R; McDowell KA; Nickel KP; Mattison RJ; Weiss M; Chappell R; Rogus-Pulia NM; Galipeau J; Kimple RJ Cytotherapy; 2023 Nov; 25(11):1139-1144. PubMed ID: 37589639 [TBL] [Abstract][Full Text] [Related]
11. Pathophysiology and management of radiation-induced xerostomia. Berk LB; Shivnani AT; Small W J Support Oncol; 2005; 3(3):191-200. PubMed ID: 15915820 [TBL] [Abstract][Full Text] [Related]
12. Mesenchymal Stromal/Stem Cell Therapy Improves Salivary Flow Rate in Radiation-Induced Salivary Gland Hypofunction in Preclinical in vivo Models: A Systematic Review and Meta-Analysis. Carlander AF; Gundestrup AK; Jansson PM; Follin B; Hoeeg C; Kousholt BS; Larsen RT; Jakobsen KK; Rimborg S; Fischer-Nielsen A; Grønhøj C; Buchwald CV; Lynggaard CD Stem Cell Rev Rep; 2024 May; 20(4):1078-1092. PubMed ID: 38430363 [TBL] [Abstract][Full Text] [Related]
13. Evidence for early and persistent impairment of salivary gland excretion after irradiation of head and neck tumours. Liem IH; Olmos RA; Balm AJ; Keus RB; van Tinteren H; Takes RP; Muller SH; Bruce AM; Hoefnagel CA; Hilgers FJ Eur J Nucl Med; 1996 Nov; 23(11):1485-90. PubMed ID: 8854847 [TBL] [Abstract][Full Text] [Related]
14. Impact of submandibular gland excision on salivary gland function in head and neck cancer patients. Jaguar GC; Lima EN; Kowalski LP; Pellizon AC; Carvalho AL; Alves FA Oral Oncol; 2010 May; 46(5):349-54. PubMed ID: 20227906 [TBL] [Abstract][Full Text] [Related]
15. The role of stem cells in the prevention and treatment of radiation-induced xerostomia in patients with head and neck cancer. Nevens D; Nuyts S Cancer Med; 2016 Jun; 5(6):1147-53. PubMed ID: 26880659 [TBL] [Abstract][Full Text] [Related]
16. Diffusion-weighted imaging as a follow-up modality for evaluation of major salivary gland function in nasopharyngeal carcinoma patients: a preliminary study. Fan WJ; Teng F; Luo YR; Yu W; Zhang Q; Lu YP; Ma L Strahlenther Onkol; 2020 Jun; 196(6):530-541. PubMed ID: 32025803 [TBL] [Abstract][Full Text] [Related]
17. Does hyperbaric oxygen treatment have the potential to increase salivary flow rate and reduce xerostomia in previously irradiated head and neck cancer patients? A pilot study. Forner L; Hyldegaard O; von Brockdorff AS; Specht L; Andersen E; Jansen EC; Hillerup S; Nauntofte B; Jensen SB Oral Oncol; 2011 Jun; 47(6):546-51. PubMed ID: 21493124 [TBL] [Abstract][Full Text] [Related]
18. Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers. Vissink A; Mitchell JB; Baum BJ; Limesand KH; Jensen SB; Fox PC; Elting LS; Langendijk JA; Coppes RP; Reyland ME Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):983-91. PubMed ID: 20970030 [TBL] [Abstract][Full Text] [Related]
19. Clinical effectiveness and safety of acupuncture in the treatment of irradiation-induced xerostomia in patients with head and neck cancer: a systematic review. O'Sullivan EM; Higginson IJ Acupunct Med; 2010 Dec; 28(4):191-9. PubMed ID: 21062848 [TBL] [Abstract][Full Text] [Related]
20. Dramatic and prolonged decrease of whole salivary secretion in nasopharyngeal carcinoma patients treated with radiotherapy. Jen YM; Lin YC; Wang YB; Wu DM Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Mar; 101(3):322-7. PubMed ID: 16504865 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]